• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

BiPar to Start Brain Cancer Clinical Program

Posted on: Friday, 11 April 2008, 12:00 CDT

Drug development company BiPar Sciences has announced the expansion of the clinical program for the company's lead product candidate, BSI-201, into glioblastoma multiforme, the most common glioma in adults.

BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in BiPar's DNA repair portfolio, crosses the blood-brain barrier, a unique property that enables its targeted investigation in the brain tumor setting. This study is being conducted by investigators from the New Approaches to Brain Tumor Therapy (NABTT) consortium, a National Cancer Institute-funded research group.

In addition to GBM, BiPar is currently enrolling BSI-201 in a randomized Phase II trial for triple-negative breast cancer and is initiating Phase II trials in uterine and BRCA-negative ovarian cancers.

Barry Sherman, BiPar's executive vice president, said: "The scientific observations that BSI-201 crosses the blood-brain barrier and has a mechanistic basis to synergize with the standard treatment of glioblastoma multiforme (GBM) makes this a promising study. It is the promise of this approach that encouraged the leaders of NABTT to evaluate BSI-201 in patients with GBM."

Source: Datamonitor

More News in this Category